We can judge whether Adverum Biotechnologies, Inc. (NASDAQ:ADVM) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Adverum Biotechnologies, Inc. ADVM announced that it has completed the investigational new drug (“IND”) amendment with the FDA to begin a mid-stage study on its gene therapy candidate, ADVM-022, for ...
ADVM-022 has had a problem with ocular inflammation. The company has never addressed the issue in a trial. Now, a loss of vision in a patient may doom the gene therapy. Looking for more investing ...
) has been revised to $11.42 / share. This is a decrease of 42.56% from the prior estimate of $19.89 dated September 27, 2025. The price target is an average of many targets provided by analysts. The ...
Adverum will sell the shares at a price per share of $1.20, representing a premium of approximately 20% to its stock’s 30-day volume-weighted average price, and the financing is expected to close on ...
Adverum Biotechnologies Inc (NASDAQ:ADVM) released data from its ongoing LUNA Phase 2 trial for Ixo-vec in patients with wet age-related macular degeneration (AMD). The 26-week interim analysis was ...
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here. Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company ...
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its INFINITY clinical ...
Adverum Biotechnologies stock rose 20% over the last 10 trading days (2 weeks), compared to the broader market (S&P500) rise of 3.5% A change of 20% or more over 10 trading days is a 33% likelihood ...
Adverum Biotechnologies, Inc. ADVM announced that it has received feedback from the FDA on its investigational new drug (IND) application for initiating a phase II study to evaluate its eye disorder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results